Value Microcaps Motherboard

[whyme2005]

DYNT $1.3 WILL REPORT 4Q 2006 EARNINGS NEXT WEEK....... GREAT ENTRY POINT UNDER $1.5

TARGET: $3++ by YEAR END

Earnings for the quarter and for the year 2006 will be decent, still pritable, but not great ...and that is one of the reasons why it is trading in the low $1's. However, it is likely that DYNT will have several strong quarters starting with 1Q 2007 to be reported in early November. Early this month, DYNT released its high-margin and long-awaited Dynatron X3 Light Therapy Unit.

Mr. Cullimore, President of Dynatronics said about this release.."While we have been delayed in releasing the new X3 product, we are confident the market will be pleased with the outcome. The delay has created a backlog of orders that we hope to resolve over the next few weeks,"

The company belives that the stock is undervalued and is buying back stock in the open market. Mr Cullimore said:

..."On another front, the $500,000 stock buy-back program that was announced by Dynatronics is well underway. The company is again actively purchasing its common shares on the open market. Since announcing the program in 2003, Dynatronics has purchased 134,000 shares of common stock in the open market. "Reactivating our stock repurchase program highlights the current undervaluation of our stock,"

That's the type of confidence that you don't hear from companies trading this low. Now that investors are looking for safe investment, they will be hard pressed to find safer investments than DYNT at these prices.

Here is the release that explains about the X3 and the stock buyback:

http://biz.yahoo.com/prnews/060803/lath058.html?.v=64


DYNT HIGHLIGHTS:


* DYNT IS THE LEADER IN LIGHT THERAPY FOR PAIN MANAGEMENT

* FDA APPROVED PRODUCTS

* NEW PRODUCTS WILL YIELD SUBSTANTIAL GAINS IN REVENUE AND NET INCOME STARTING with 1Q 2007 WITH TOMORROW'S NUMBERS.

* PROFITABLE AND TRADING AT 0.5 P/S

* STRONG BALANCE SHEET


DYNT is the leader in the area of light therapy for pain management. DYNT's Light therapy products are FDA-approved. In fact, it was widely publicized that one of Dynatronics' light therapy probes was use to accelerate Terrel Owens' amazing recovery in time to play in the Superbowl a couple of years ago.

DYNT has started shipping several new pain-management products in recent months and are expected to boost revenues and net income starting in 1Q 2007 to be reported in early November 2006. DYNT had never before launched so many new products before. Revenue and net income usually jump in the quarters following the deployment of new products.

Because light therapy is non-invasive and does not have adverse effects, it is an ideal replacement for dangerous drugs like Vioxx, and Celebrex to address Rheumatism and similar types of pain. Light therapy is also used for carpal syndrome and a number of muscle/nerve/bone types of pain.

Light Therapy has been used extensively throughout the world for more than twenty years. Also known as cold laser or phototherapy, Light Therapy is backed by extensive research with over 500 published studies covering a number of soft-tissue injuries, pain, and inflammatory conditions.

DYNT has introduced a number of new state-of-the-art pain management products at the end of last quarter and this quarter:

New products include the Dynatron X3 multiple modality infrared light therapy device, the DX2 proprietary traction device that incorporates unique technology, and the T4 therapy table specially designed for performing traction and decompression therapies. These products will expand the range of decompression and light therapy treatment options for treating back pain.

"The introduction of these state-of-the-art products will give additional impetus to the growth of sales and profits in future quarters," added CEO Cullimore......


Insiders have been loading up lately, and the company has been buying stock in the open market.


Do your DD